Evidence map›Paper›PMID 34502457›Full record

ArticleInternational journal of molecular sciences2021

Dual

Rubén Darío Castro-Torres, Jordi Olloquequi, Miren Etchetto, Pablo Caruana, Luke Steele, Kyra-Mae Leighton, Jesús Ureña, Carlos Beas-Zarate, Antoni Camins, Ester Verdaguer and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. MKK4 Inhibitors-Recent Development Status and Therapeutic Potential.International journal of molecular sciences · 2023
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Rubén Darío Castro-TorresDepartment of Cell Biology, Physiology and Immunology, Biology Faculty, Universitat de Barcelona, 08028 Barcelona, Spain.ORCID 0000-0003-3334-3096
Jordi OlloquequiLaboratory of Cellular and Molecular Pathology, Health Sciences Faculty, Biomedical Sciences Institute, Universidad Autónoma de Chile, Talca 3460000, Chile.
Miren EtchettoDepartment of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacy and Food Sciences Faculty, Universitat de Barcelona, 08028 Barcelona, Spain.ORCID 0000-0002-4301-7297
Pablo CaruanaDepartment of Cell Biology, Physiology and Immunology, Biology Faculty, Universitat de Barcelona, 08028 Barcelona, Spain.
Luke SteeleDepartment of Cell Biology, Physiology and Immunology, Biology Faculty, Universitat de Barcelona, 08028 Barcelona, Spain.
Kyra-Mae LeightonDepartment of Cell Biology, Physiology and Immunology, Biology Faculty, Universitat de Barcelona, 08028 Barcelona, Spain.
Jesús UreñaDepartment of Cell Biology, Physiology and Immunology, Biology Faculty, Universitat de Barcelona, 08028 Barcelona, Spain.
Carlos Beas-ZarateLaboratory of Neurobiotechnology CUCBA, Department of Cell and Molecular Biology, Universidad de Guadalajara, Jalisco 45200, Mexico.
Antoni CaminsDepartment of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacy and Food Sciences Faculty, Universitat de Barcelona, 08028 Barcelona, Spain.ORCID 0000-0002-1229-5956
Ester VerdaguerDepartment of Cell Biology, Physiology and Immunology, Biology Faculty, Universitat de Barcelona, 08028 Barcelona, Spain.
Carme AuladellDepartment of Cell Biology, Physiology and Immunology, Biology Faculty, Universitat de Barcelona, 08028 Barcelona, Spain.ORCID 0000-0001-8345-1859
Instituto de Salud Carlos III · ESUniversitat de Barcelona · ESUniversidad de Guadalajara · MXUniversidad Autónoma de Chile · CL

Funding

CentroInvestigación Biomédica en Red CB06/05/0024 (CIBERNEDThe Spanish Ministry of Science and Innovation AF2017-84283-R, PI2016/01;CB06/05/0024 (CIBERNED).
6 · The paper itself

Abstract

(1) Background: The c-Jun-NH2-terminal protein kinase (JNK) is a mitogen-activated protein kinase involved in regulating physiological processes in the central nervous system. However, the dual genetic deletion of

Indexed as

MAP Kinase Signaling SystemNeurogenesisAnimalsDoublecortin ProteinGene DeletionHippocampusMAP Kinase Kinase 4MAP Kinase Kinase 7Mice, TransgenicDcx protein, mouseDoublecortin ProteinMap2k7 protein, mouseMAP Kinase Kinase 4MAP Kinase Kinase 7Cre-LoxPDCXhippocampusMKK4MKK7pJNK

Identifiers

PMID34502457
PMCPMC8430506
OpenAlexW3197890058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.